Table of Contents
ISRN Neuroendocrinology
Volume 2012 (2012), Article ID 874350, 11 pages
http://dx.doi.org/10.5402/2012/874350
Review Article

Profiling of GEPNETs

Sahlgrenska Cancer Centre and Department of Biomedicine, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden

Received 26 September 2011; Accepted 20 October 2011

Academic Editors: Y. J. Chen, S. De Dosso, G. Procopio, and D. van West

Copyright © 2012 Ola Nilsson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. C. Yao, M. Hassan, A. Phan et al., “One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States,” Journal of Clinical Oncology, vol. 26, no. 18, pp. 3063–3072, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. I. M. Modlin, K. Öberg, D. C. Chung et al., “Gastroenteropancreatic neuroendocrine tumours,” The Lancet Oncology, vol. 9, no. 1, pp. 61–72, 2008. View at Publisher · View at Google Scholar
  3. F. T. Bosman, F. Carnerio, R. H. Hruban, and N. D. Theise, Eds., WHO Classification of Tumours of the Digestive System, IARC, Lyon, France, 4th edition, 2010.
  4. M. Meyerson, S. Gabriel, and G. Getz, “Advances in understanding cancer genomes through second-generation sequencing,” Nature Reviews Genetics, vol. 11, no. 10, pp. 685–696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. K. Cowell and L. Hawthorn, “The application of microarray technology to the analysis of the cancer genome,” Current Molecular Medicine, vol. 7, no. 1, pp. 103–120, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. D. S. P. Tan, M. B. K. Lambros, R. Natrajan, and J. S. Reis-Filho, “Getting it right: designing microarray (and not “microawry”) comparative genomic hybridization studies for cancer research,” Laboratory Investigation, vol. 87, no. 8, pp. 737–754, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. C. G. Liu, R. Spizzo, G. A. Calin, and C. M. Croce, “Expression profiling of microRNA using oligo DNA arrays,” Methods, vol. 44, no. 1, pp. 22–30, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. D. K. Nomura, M. M. Dix, and B. F. Cravatt, “Activity-based protein profiling for biochemical pathway discovery in cancer,” Nature Reviews Cancer, vol. 10, no. 9, pp. 630–638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. N. Zikusoka, M. Kidd, G. Eick, I. Latich, and I. M. Modlin, “The molecular genetics of gastroenteropancreatic neuroendocrine tumors,” Cancer, vol. 104, no. 11, pp. 2292–2309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. E. M. Duerr and D. C. Chung, “Molecular genetics of neuroendocrine tumors,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 21, no. 1, pp. 1–14, 2007. View at Publisher · View at Google Scholar
  11. K. Öberg, “Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors),” Current Opinion in Endocrinology, Diabetes and Obesity, vol. 16, no. 1, pp. 72–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Calender, “Molecular genetics of neuroendocrine tumors,” Digestion, vol. 62, no. 1, pp. 3–18, 2000. View at Google Scholar · View at Scopus
  13. S. C. Chandrasekharappa, S. C. Guru, P. Manickam et al., “Positional cloning of the gene for multiple endocrine neoplasia-type 1,” Science, vol. 276, no. 5311, pp. 404–406, 1997. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Latif, K. Tory, J. Gnarra et al., “Identification of the von Hippel-Lindau disease tumor suppressor gene,” Science, vol. 260, no. 5112, pp. 1317–1320, 1993. View at Google Scholar · View at Scopus
  15. D. Viskochil, A. M. Buchberg, G. Xu et al., “Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus,” Cell, vol. 62, no. 1, pp. 187–192, 1990. View at Publisher · View at Google Scholar · View at Scopus
  16. Z. Zhuang, A. O. Vortmeyer, S. Pack et al., “Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas,” Cancer Research, vol. 57, no. 21, pp. 4682–4686, 1997. View at Google Scholar · View at Scopus
  17. E. H. Wang, S. A. Ebrahimi, A. Y. Wu, C. Kashefi, E. Passaro Jr., and M. P. Sawicki, “Mutation of the MENIN gene in sporadic pancreatic endocrine tumors,” Cancer Research, vol. 58, no. 19, pp. 4417–4420, 1998. View at Google Scholar · View at Scopus
  18. B. Görtz, J. Roth, A. Krähenmann et al., “Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms,” American Journal of Pathology, vol. 154, no. 2, pp. 429–436, 1999. View at Google Scholar
  19. P. S. Moore, E. Missiaglia, D. Antonello et al., “Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL,” Genes Chromosomes and Cancer, vol. 32, no. 2, pp. 177–181, 2001. View at Publisher · View at Google Scholar
  20. V. Corbo, I. Dalai, M. Scardoni et al., “MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases,” Endocrine-Related Cancer, vol. 17, no. 3, pp. 771–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. E. J. M. Speel, J. Richter, H. Moch et al., “Genetic differences in endocrine pancreatic tumor subtypes detected by comparative genomic hybridization,” American Journal of Pathology, vol. 155, no. 6, pp. 1787–1794, 1999. View at Google Scholar · View at Scopus
  22. E. J. M. Speel, A. F. Scheidweiler, J. Zhao et al., “Genetic evidence for early divergence of small functioning and nonfunctioning endocrine pancreatic tumors: gain of 9Q34 is an early event in insulinomas,” Cancer Research, vol. 61, no. 13, pp. 5186–5192, 2001. View at Google Scholar · View at Scopus
  23. J. Zhao, H. Moch, A. F. Scheidweiler et al., “Genomic imbalances in the progression of endocrine pancreatic tumors,” Genes Chromosomes and Cancer, vol. 32, no. 4, pp. 364–372, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Stumpf, Y. Aalto, A. Höög et al., “Chromosomal alterations in human pancreatic endocrine tumors,” Genes Chromosomes and Cancer, vol. 29, no. 1, pp. 83–87, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Barghorn, P. Komminoth, D. Bachmann et al., “Deletion at 3p25.3-p23 is frequently encountered in endocrine pancreatic tumours and is associated with metastatic progression,” Journal of Pathology, vol. 194, no. 4, pp. 451–458, 2001. View at Google Scholar · View at Scopus
  26. A. Barghorn, E. J. M. Speel, B. Farspour et al., “Putative tumor suppressor loci at 6q22 and 6q23-q24 are involved in the malignant progression of sporadic endocrine pancreatic tumors,” American Journal of Pathology, vol. 158, no. 6, pp. 1903–1911, 2001. View at Google Scholar · View at Scopus
  27. S. S. Guo, A. Y. Wu, and M. P. Sawicki, “Deletion of chromosome 1, but not mutation of MEN-1, predicts prognosis in sporadic pancreatic endocrine tumors,” World Journal of Surgery, vol. 26, no. 7, pp. 843–847, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. Y. M. H. Jonkers, S. M. H. Claessen, J. A. Veltman et al., “Molecular parameters associated with insulinoma progression: chromosomal instability versus p53 and CK19 status,” Cytogenetic and Genome Research, vol. 115, no. 3-4, pp. 289–297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. K. T. Flaherty, I. Puzanov, K. B. Kim et al., “Inhibition of mutated, activated BRAF in metastatic melanoma,” The New England Journal of Medicine, vol. 363, no. 9, pp. 809–819, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. de Raedt, Z. Walton, J. Yecies et al., “Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors,” Cancer Cell, vol. 20, no. 3, pp. 400–413, 2011. View at Publisher · View at Google Scholar
  31. Y. M. H. Jonkers, S. M. H. Claessen, T. Feuth et al., “Novel candidate tumour suppressor gene loci on chromosomes 11q23-24 and 22q13 involved in human isulinoma tumourigenesis,” Journal of Pathology, vol. 210, no. 4, pp. 450–458, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Deshpande, S. Roman, J. Thumar, and J. A. Sosa, “Vandetanib (ZD6474) in the treatment of medullary thyroid cancer,” Clinical Medicine Insights: Oncology, vol. 5, pp. 213–221, 2011. View at Google Scholar
  33. D. S. Hong, M. E. Cabanillas, J. Wheler et al., “Inhibition of the ras/raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies,” Journal of Clinical Endocrinology and Metabolism, vol. 96, no. 4, pp. 997–1005, 2011. View at Publisher · View at Google Scholar
  34. M. L. Gild, M. Bullock, B. G. Robinson, and R. Clifton-Bligh, “Multikinase inhibitors: a new option for the treatment of thyroid cancer,” Nature Reviews Endocrinology, vol. 7, no. 10, pp. 617–624, 2011. View at Publisher · View at Google Scholar
  35. Y. Nagano, H. K. Do, L. Zhang et al., “Allelic alterations in pancreatic endocrine tumors identified by genome-wide single nucleotide polymorphism analysis,” Endocrine-Related Cancer, vol. 14, no. 2, pp. 483–492, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. M. F. Maritz, C. E. Napier, V. W. Wen, and K. L. MacKenzie, “Targeting telomerase in hematologic malignancy,” Future Oncology, vol. 6, no. 5, pp. 769–789, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. S. Ramalingam, J. W. Lee, C. P. Belani et al., “Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504),” Journal of Clinical Oncology, vol. 29, no. 13, pp. 1709–1714, 2011. View at Publisher · View at Google Scholar
  38. T. S. Maughan, R. A. Adams, C. G. Smith et al., “Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial,” The Lancet, vol. 377, no. 9783, pp. 2103–2114, 2011. View at Publisher · View at Google Scholar
  39. W. Hu, Z. Feng, I. Modica et al., “Gene amplifications in well-differentiated pancreatic neuroendocrine tumors inactivate the p53 pathway,” Genes and Cancer, vol. 1, no. 4, pp. 360–368, 2010. View at Publisher · View at Google Scholar
  40. L. T. Vassilev, B. T. Vu, B. Graves et al., “In vivo activation of the p53 pathway by small-molecule antagonists of MDM2,” Science, vol. 303, no. 5659, pp. 844–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Jiao, C. Shi, B. H. Edil et al., “DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors,” Science, vol. 331, no. 6021, pp. 1199–1203, 2011. View at Publisher · View at Google Scholar
  42. C. M. Heaphy, R. F. de Wilde, Y. Jiao et al., “Altered telomeres in tumors with ATRX and DAXX mutations,” Science, vol. 333, no. 6041, p. 425, 2011. View at Publisher · View at Google Scholar
  43. J. C. Yao, A. T. Phan, D. Z. Chang et al., “Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study,” Journal of Clinical Oncology, vol. 26, no. 26, pp. 4311–4318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. J. C. Yao, M. H. Shah, T. Ito et al., “Everolimus for advanced pancreatic neuroendocrine tumors,” The New England Journal of Medicine, vol. 364, no. 6, pp. 514–523, 2011. View at Publisher · View at Google Scholar
  45. A. Maitra, D. E. Hansel, P. Argani et al., “Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays,” Clinical Cancer Research, vol. 9, no. 16, part 1, pp. 5988–5995, 2003. View at Google Scholar · View at Scopus
  46. D. E. Hansel, A. Rahman, M. House et al., “Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms,” Clinical Cancer Research, vol. 10, no. 18, part 1, pp. 6152–6158, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Bloomston, A. Durkin, I. Yang et al., “Identification of molecular markers specific for pancreatic neuroendocrine tumors by genetic profiling of core biopsies,” Annals of Surgical Oncology, vol. 11, no. 4, pp. 413–419, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. W. G. Dilley, S. Kalyanaraman, S. Verma, J. P. Cobb, J. M. Laramie, and T. C. Lairmore, “Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome,” Molecular Cancer, vol. 4, no. 1, p. 9, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. G. Capurso, S. Lattimore, T. Crnogorac-Jurcevic et al., “Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets,” Endocrine-Related Cancer, vol. 13, no. 2, pp. 541–558, 2006. View at Publisher · View at Google Scholar · View at Scopus
  50. A. W. Lowe, M. Olsen, Y. Hao et al., “Gene expression patterns in pancreatic tumors, cells and tissues,” PLoS ONE, vol. 2, no. 3, p. e323, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. S. V. de Sá, M. L. Corrêa-Giannella, M. C. Machado et al., “Serpin peptidase inhibitor clade A member 1 as a potential marker for malignancy in insulinomas,” Clinical Cancer Research, vol. 13, no. 18, part 1, pp. 5322–5330, 2007. View at Publisher · View at Google Scholar · View at Scopus
  52. A. Couvelard, J. Hu, G. Steers et al., “Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors,” Gastroenterology, vol. 131, no. 5, pp. 1597–1610, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Heidegger, A. Pircher, H. Klocker, and P. Massoner, “Targeting the insulin-like growth factor network in cancer therapy,” Cancer Biology and Therapy, vol. 11, no. 8, pp. 701–707, 2011. View at Publisher · View at Google Scholar
  54. Y. Tao, V. Pinzi, J. Bourhis, and E. Deutsch, “Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer,” Nature Clinical Practice Oncology, vol. 4, no. 10, pp. 591–602, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. F. M. Yakes, J. Chen, J. Tan et al., “Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously 7 suppresses metastasis, angiogenesis, and tumor growth,” Molecular Cancer Therapeutics, vol. 10, no. 12, pp. 2298–2308, 2011. View at Google Scholar
  56. X. Liu, Q. Wang, G. Yang et al., “A novel kinase inhibitor INCB28060 blocks c-MET-dependent signaling, neoplastic activities, and crosstalk with EGFR and HER-3,” Clinical Cancer Research, vol. 17, no. 22, pp. 7127–7138, 2011. View at Google Scholar
  57. T. A. Yap, S. K. Sandhu, S. M. Alam, and J. S.. de Bono, “HGF/c-MET targeted therapeutics: novel strategies for cancer medicine,” Current Drug Targets. In press.
  58. J. L. Brown, Z. A. Cao, M. Pinzon-Ortiz et al., “A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models,” Molecular Cancer Therapeutics, vol. 9, no. 1, pp. 145–156, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. J. C. Montero, S. Seoane, A. Ocaña, and A. Pandiella, “Inhibition of Src family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors,” Clinical Cancer Research, vol. 17, no. 17, pp. 5546–5552, 2011. View at Publisher · View at Google Scholar
  60. E. M. Duerr, Y. Mizukami, A. Ng et al., “Defining molecular classifications and targets in gastroenteropancreatic neuroendocrine tumors through DNA microarray analysis,” Endocrine-Related Cancer, vol. 15, no. 1, pp. 243–256, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. E. Missiaglia, I. Dalai, S. Barbi et al., “Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway,” Journal of Clinical Oncology, vol. 28, no. 2, pp. 245–255, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. D. J. Kwekkeboom, W. W. de Herder, and E. P. Krenning, “Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors,” Endocrinology and Metabolism Clinics of North America, vol. 40, no. 1, pp. 173–185, 2011. View at Publisher · View at Google Scholar
  63. C. Roldo, E. Missiaglia, J. P. Hagan et al., “MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior,” Journal of Clinical Oncology, vol. 24, no. 29, pp. 4677–4684, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. R. M. Löllgen, O. Hessman, E. Szabo, G. Westin, and G. Åkerström, “Chromosome 18 deletions are common events in classical midgut carcinoid tumors,” International Journal of Cancer, vol. 92, no. 6, pp. 812–815, 2001. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Tönnies, M. R. Toliat, C. Ramel et al., “Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation,” Gut, vol. 48, no. 4, pp. 536–541, 2001. View at Publisher · View at Google Scholar · View at Scopus
  66. S. Kytölä, A. Höög, B. Nord et al., “Comparative genomic hybridization identifies loss of 18q22-qter as an early and specific event in tumorigenesis of midgut carcinoids,” American Journal of Pathology, vol. 158, no. 5, pp. 1803–1808, 2001. View at Google Scholar · View at Scopus
  67. G. G. Wang, J. C. Yao, S. Worah et al., “Comparison of genetic alterations in neuroendocrine tumors: frequent loss of chromosome 18 in ileal carcinoid tumors,” Modern Pathology, vol. 18, no. 8, pp. 1079–1087, 2005. View at Publisher · View at Google Scholar · View at Scopus
  68. H. K. Do, Y. Nagano, I. S. Choi, J. A. White, J. C. Yao, and A. Rashid, “Allelic alterations in well-differentiated neuroendocrine tumors (carcinoid tumors) identified by genome-wide single nucleotide polymorphism analysis and comparison with pancreatic endocrine tumors,” Genes Chromosomes and Cancer, vol. 47, no. 1, pp. 84–92, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. M. H. Kulke, E. Freed, D. Y. Chiang et al., “High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss,” Genes Chromosomes and Cancer, vol. 47, no. 7, pp. 591–603, 2008. View at Publisher · View at Google Scholar · View at Scopus
  70. E. Andersson, C. Swärd, G. Stenman, H. Ahlman, and O. Nilsson, “High-resolution genomic profiling reveals gain of chromosome 14 as a predictor of poor outcome in ileal carcinoids,” Endocrine-Related Cancer, vol. 16, no. 3, pp. 953–966, 2009. View at Publisher · View at Google Scholar · View at Scopus
  71. J. L. Cunningham, T. D. de Ståhl, T. Sjöblom, G. Westin, J. P. Dumanski, and E. T. Janson, “Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors,” Genes Chromosomes and Cancer, vol. 50, no. 2, pp. 82–94, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. Y. Arvidsson, E. Andersson, A. Bergström et al., “Amyloid precursor-like protein 1 is differentially upregulated in neuroendocrine tumours of the gastrointestinal tract,” Endocrine-Related Cancer, vol. 15, no. 2, pp. 569–581, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Leja, A. Essaghir, M. Essand et al., “Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas,” Modern Pathology, vol. 22, no. 2, pp. 261–272, 2009. View at Publisher · View at Google Scholar
  74. K. Edfeldt, P. Björklund, G. Åkerström, G. Westin, P. Hellman, and P. Stålberg, “Different gene expression profiles in metastasizing midgut carcinoid tumors,” Endocrine-Related Cancer, vol. 18, no. 4, pp. 479–489, 2011. View at Publisher · View at Google Scholar
  75. K. Ruebel, A. A. Leontovich, G. A. Stilling et al., “MicroRNA expression in ileal carcinoid tumors: downregulation of microRNA-133a with tumor progression,” Modern Pathology, vol. 23, no. 3, pp. 367–375, 2010. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Gaur, E. L. Sceusi, S. Samuel et al., “Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors,” Gastroenterology, vol. 141, no. 5, pp. 1728–1737, 2011. View at Google Scholar